JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer

Core Insights - Johnson & Johnson (J&J) received European Commission approval for the expanded use of its precision therapy Akeega in treating BRCA1/2-mutated metastatic hormone-sensitive prostate cancer [2][7] - The approval is based on the phase III AMPLITUDE study, which demonstrated that the Akeega-prednisone combination significantly delays disease progression, reducing the risk of progression or death by nearly 50% compared to standard care [3][7] - J&J's oncology segment accounts for approximately 27% of total revenues, with expectations to reach $50 billion in oncology sales by 2030, driven by strong growth in existing cancer drugs and new product launches [11] Regulatory Approvals - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Akeega's indication extension in January 2026 [4] - Akeega was previously approved in the EU for BRCA-mutated metastatic castration-resistant prostate cancer in 2023 [4][10] - The FDA approved Akeega in combination with prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer in December 2025, marking a significant milestone in precision medicine [9][10] Market Performance - Over the past six months, J&J's shares have increased by 35.9%, outperforming the industry average increase of 19.7% [5] Product Composition - Akeega combines the PARP inhibitor niraparib and the CYP17 inhibitor abiraterone acetate, with J&J holding exclusive rights to niraparib for prostate cancer [8]